0000950170-23-031207.txt : 20230630 0000950170-23-031207.hdr.sgml : 20230630 20230630182914 ACCESSION NUMBER: 0000950170-23-031207 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230628 FILED AS OF DATE: 20230630 DATE AS OF CHANGE: 20230630 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MacDonald Brian Richard CENTRAL INDEX KEY: 0001952556 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39438 FILM NUMBER: 231063093 MAIL ADDRESS: STREET 1: C/O DISC MEDICINE, INC. STREET 2: 321 ARSENAL STREET, SUITE 101 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Disc Medicine, Inc. CENTRAL INDEX KEY: 0001816736 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851613057 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 ONE KENDALL SQUARE, 3RD FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: (617) 401-4400 MAIL ADDRESS: STREET 1: 300 ONE KENDALL SQUARE, 3RD FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Gemini Therapeutics, Inc. /DE DATE OF NAME CHANGE: 20210209 FORMER COMPANY: FORMER CONFORMED NAME: FS Development Corp. DATE OF NAME CHANGE: 20200702 4 1 ownership.xml 4 X0407 4 2023-06-28 0001816736 Disc Medicine, Inc. IRON 0001952556 MacDonald Brian Richard C/O DISC MEDICINE, INC. 321 ARSENAL STREET, SUITE 101 WATERTOWN MA 02472 false true false false Chief Innovation Officer true Common Stock 2023-06-28 4 S false 2247 49.2430 D 25153 D Common Stock 2023-06-28 4 S false 1900 50.3844 D 23253 D Common Stock 2023-06-28 4 S false 953 50.8032 D 22300 D Common Stock 2023-06-29 4 S false 736 44.3698 D 21564 D Common Stock 2023-06-29 4 S false 2230 45.4946 D 19334 D Common Stock 2023-06-29 4 S false 1934 46.5110 D 17400 D Common Stock 2023-06-29 4 S false 200 47.2400 D 17200 D Common Stock 2023-06-30 4 S false 2923 44.8518 D 14277 D Common Stock 2023-06-30 4 S false 1401 45.4506 D 12876 D Common Stock 2023-06-30 4 S false 600 46.7633 A 12276 D Common Stock 1096 I Held by Son Common Stock 1096 I Held by Son Common Stock 1096 I Held by Son The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.61 to $49.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (11) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.61 to $50.59, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.62 to $51.235, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.87, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.03 to $45.94, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.04 to $46.96, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.23 to $47.25, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.31 to $45.29, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.31 to $45.58, inclusiv The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.56 to $47.00, inclusive. The Reporting Person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly. By: /s/ Rahul Khara, as Attorney-in-Fact 2023-06-30